Fourth Pfizer Dose Is Insufficient to Ward Off Omicron, Israeli Trial Suggests
- Preliminary data found inoculation did increase antibodies
- Those with 4th shot only slightly less likely to get variant
This article is for subscribers only.
A fourth dose of the Pfizer-BioNTech vaccine was insufficient to prevent infection with the omicron variant of Covid-19, according to preliminary data from a trial in Israel released Monday.
Two weeks after the start of the trial of 154 medical personnel at the Sheba Medical Center in Tel Aviv, researchers found the vaccine raised antibody levels.